Form 13-F position report

COCRYSTAL PHARMA INC

Reported by BlackRock Inc

COCP CUSIP 19188J409 Manager CIK 0001364742

Reported 73,746 shares, unchanged from the prior quarter.

Reported value 66.4%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 73,746 Quarter-end amount reported
Reported value $171,828 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 144423
2023-03-31 147385
2023-06-30 177011
2023-09-30 138498
2023-12-31 127551
2024-03-31 103244
2024-06-30 171828
2024-09-30 129793
2024-12-31 148967
2025-03-31 104719
2025-06-30 109882
2025-09-30 92183
2025-12-31 72197
2026-03-31 74483
2026-06-30 77433
2026-09-30 84808

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for COCRYSTAL PHARMA INC held by BlackRock Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 73,746 0 (0.0%) < 0.01% $84,808 2026-11-13
Q2 2026 Unchanged 73,746 0 (0.0%) < 0.01% $77,433 2026-08-07
Q1 2026 Unchanged 73,746 0 (0.0%) < 0.01% $74,483 2026-05-13
Q4 2025 Unchanged 73,746 0 (0.0%) < 0.01% $72,197 2026-02-12
Q3 2025 Unchanged 73,746 0 (0.0%) < 0.01% $92,183 2025-11-12
Q2 2025 Unchanged 73,746 0 (0.0%) < 0.01% $109,882 2025-08-12
Q1 2025 Unchanged 73,746 0 (0.0%) < 0.01% $104,719 2025-05-02
Q4 2024 Unchanged 73,746 0 (0.0%) < 0.01% $148,967 2025-02-07
Q3 2024 New 73,746 +73,746 (0.0%) < 0.01% $129,793 2024-11-13
Q2 2024 Unchanged 73,746 0 (0.0%) < 0.01% $171,828 2024-08-13
Q1 2024 Reduced 73,746 -317 (-0.4%) < 0.01% $103,244 2024-05-10
Q4 2023 Unchanged 74,063 0 (0.0%) < 0.01% $127,551 2024-02-13
Q3 2023 Unchanged 74,063 0 (0.0%) < 0.01% $138,498 2023-11-13
Q2 2023 Unchanged 74,063 0 (0.0%) < 0.01% $177,011 2023-08-11
Q1 2023 Unchanged 74,063 0 (0.0%) < 0.01% $147,385 2023-05-12
Q4 2022 New 74,063 +74,063 (0.0%) < 0.01% $144,423 2023-02-13

Who else reported the position

18 managers reported COCRYSTAL PHARMA INC for Q2 2024.

Managers reporting COCRYSTAL PHARMA INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Unchanged 275,656 0 < 0.01% $642,278 7 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 129,828 +3,800 < 0.01% $302,499 7 qtrs
BlackRock Inc This report Unchanged 73,746 0 < 0.01% $171,828 7 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 64,832 +4,400 < 0.01% $151,089 7 qtrs
MORGAN STANLEY Added 59,300 +29 < 0.01% $138,170 7 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 25,052 -27,078 < 0.01% $58,371 6 qtrs
STATE STREET CORPORATION Reduced 20,543 -3,900 < 0.01% $47,865 7 qtrs
NORTHERN TRUST CORPORATION Reduced 12,171 -36 < 0.01% $28,359 7 qtrs
Bank of America Corporation Added 9,033 +58 < 0.01% $21,047 7 qtrs
Tower Research Capital LLC TRC Reduced 3,681 -3,775 < 0.01% $8,577 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
73,746
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.